Get the Stockscreener App
29.08
0.14%
0.04
Mersana Therapeutics Inc stock is traded at $29.08, with a volume of 707.35K.
It is up +0.14% in the last 24 hours and up +4.70% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$29.04
Open:
$28.9
24h Volume:
707.35K
Relative Volume:
5.45
Market Cap:
$145.36M
Revenue:
$34.77M
Net Income/Loss:
$-74.04M
P/E Ratio:
-3.6279
EPS:
-8.0157
Net Cash Flow:
$-79.76M
1W Performance:
+1.50%
1M Performance:
+4.70%
6M Performance:
+301.80%
1Y Performance:
-14.47%
1-Day Range:
$28.78
$30.39
1-Week Range:
$28.48
$30.39
52-Week Range:
$5.21
$36.25
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
29.08 | 145.36M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.70 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.49 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
393.09 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.04 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.03 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Day One Completes Acquisition of Mersana Therapeutics - GlobeNewswire
Mersana Therapeutics, Inc.(NasdaqGS: MRSN) dropped from S&P TMI Index - marketscreener.com
Panic Selling: Is Mersana Therapeutics Inc stock positioned for long term growthWeekly Risk Report & AI Driven Stock Reports - moha.gov.vn
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSEALEX), United Security Bancshares (NasdaqUBFO), Udemy, Inc. (NasdaqUDMY), Mersana Therapeutics, Inc. (Nasdaq - GlobeNewswire Inc.
How The Mersana Deal Is Rewriting The Story Behind Day One Biopharmaceuticals Valuation - Yahoo Finance
MRSN (Mersana Therapeutics) EV-to-OCF : -1.23 (As of Dec. 22, 2025) - GuruFocus
Fund Flows: How Mersana Therapeutics Inc. (0M4) stock compares with market leadersJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - Улправда
Is Mersana Therapeutics Inc. stock trading at a premium valuationJuly 2025 Decliners & Intraday High Probability Setup Alerts - Улправда
What insider trading reveals about Mersana Therapeutics Inc. stockWeekly Stock Report & Free Community Supported Trade Ideas - Улправда
Mersana Therapeutics Earnings Notes - Trefis
Will Mersana Therapeutics Inc. stock maintain momentum in 2025July 2025 EndofMonth & High Win Rate Trade Alerts - DonanımHaber
Is Mersana Therapeutics Inc. stock a buy before product launchesLayoff News & Safe Entry Point Identification - DonanımHaber
How Mersana Therapeutics Inc. stock performs in interest rate cyclesQuarterly Market Summary & Real-Time Buy Zone Alerts - Улправда
Mersana Therapeutics, Inc.(NasdaqGS: MRSN) dropped from NASDAQ Biotechnology Index - marketscreener.com
Is Mersana Therapeutics Inc. stock cheap compared to fundamentals2025 Market WrapUp & Verified High Yield Trade Plans - Улправда
How Mersana Therapeutics Inc. (0M4) stock compares with market leaders2025 Earnings Impact & Real-Time Volume Analysis - Улправда
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Shareholder Alert: The Ademi Firm continues to investigate wheth - GuruFocus
Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Luminus Management LLC Sells 989,314 Shares of Mersana Therapeutics, Inc. $MRSN - MarketBeat
Why Analysts See Mersana’s Story Shifting To Deal And CVR Outcomes After $1B Buyout - Yahoo Finance
Halper Sadeh LLC Encourages FFWM, MRSN, FSUN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
683 Capital Management LLC Boosts Stock Position in Mersana Therapeutics, Inc. $MRSN - MarketBeat
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc.MRSN - PR Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Why The Narrative Around Day One Biopharmaceuticals Is Shifting After The Mersana Acquisition - Yahoo Finance
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-SMLR, MRSN, CDTX, and RYI - The Malaysian Reserve
Day One Biopharmaceuticals Expands with Mersana Acquisition - StocksToTrade
Is Mersana Therapeutics Inc 0M4 a good long term investmentLarge Cap Stability Picks & High Return Trading Ideas - earlytimes.in
Mersana Therapeutics (MRSN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Is Mersana Therapeutics Inc. (0M4) stock prepared for digital transitionRate Hike & Daily Growth Stock Investment Tips - Newser
Can Mersana Therapeutics Inc. (0M4) stock stage a strong rebound this quarter - Newser
Can Mersana Therapeutics Inc. (0M4) stock sustain breakout momentumJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - Newser
Why Mersana Therapeutics Inc. (0M4) stock could be next leaderJuly 2025 Opening Moves & Community Consensus Stock Picks - Newser
How Mersana Therapeutics Inc. (0M4) stock compares with top peersQuarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser
Will Mersana Therapeutics Inc. (0M4) stock attract long term capital inflowsJuly 2025 Review & Consistent Income Trade Ideas - Newser
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Will Mersana Therapeutics Inc. (0M4) stock deliver compounding returnsQuarterly Trade Report & Breakout Confirmation Alerts - Newser
Options Flow: How Mersana Therapeutics Inc. (0M4) stock compares with market leadersJuly 2025 Setups & Daily Technical Forecast Reports - moha.gov.vn
How Mersana’s Acquisition Is Changing the Story and Analyst Outlook for Investors - Yahoo Finance
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights - Sahm
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerEXAS, SEE, CDTX, and MRSN - The Malaysian Reserve
Is Mersana Therapeutics Inc. (0M4) stock a buy before new product rolloutJuly 2025 Rallies & Risk Controlled Daily Plans - moha.gov.vn
ENN Energy Holdings Announces Conditional Privatization Proposal - The Globe and Mail
683 Capital Management, LLC Increases Stake in Mersana Therapeutics Inc. - GuruFocus
Mersana Therapeutics skyrockets 200% after Day One strikes $25-per-share takeover deal - MSN
Can Mersana Therapeutics Inc. (0M4) stock test all time highsJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
Will Mersana Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 Trade Ideas & Safe Capital Growth Stock Tips - newser.com
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):